# Zelebrudomide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zelebrudomide

> Zelebrudomide, sponsored by Nurix Therapeutics, Inc. (NRIX): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zelebrudomide |
| Codes | NX-2127 |
| Sponsor | Nurix Therapeutics, Inc. (NRIX) https://sec-api.dev/companies/nrix/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001549595-25-000005): "•Re-initiated enrollment in NX-2127 Phase 1a/b trial: Following a decision in March 2024 in which the FDA lifted a manufacturing-related, partial clinical hold on the NX-2127 clinical trial, Nurix reinitiated enrollment in a dose escalation study within the current Phase 1a/1b trial, using its new chirally controlled drug product of NX-2127, a novel orally bioavailable bifunctional molecule that degrades BTK and the cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3)." https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/nrix20250113form8-kex991jpm.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-01-28, last confirmed 2026-07-09.
- SEC Form 10-Q (accession 0001549595-26-000040): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, and a Phase 2 clinical trial for bexobrutideg, and we expect to initiate a Phase 3 clinical trial for bexobrutideg in 2026." https://www.sec.gov/Archives/edgar/data/1549595/000154959526000040/nrix-20260531.htm
- SEC Form 10-Q (accession 0001549595-26-000025): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, and a Phase 2 clinical trial for bexobrutideg, and we expect to initiate a Phase 3 clinical trial for bexobrutideg in 2026." https://www.sec.gov/Archives/edgar/data/1549595/000154959526000025/nrix-20260228.htm
- SEC Form 10-K (accession 0001549595-26-000016): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, and a Phase 2 clinical trial for bexobrutideg, and we expect to initiate a Phase 3 clinical trial for bexobrutideg in 2026." https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm
- SEC Form 10-Q (accession 0001549595-25-000113): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg (NX-5948), zelebrudomide (NX-2127) and NX-1607, and we expect to initiate a Phase 2 clinical trial of bexobrutideg in 2025." https://www.sec.gov/Archives/edgar/data/1549595/000154959525000113/nrix-20250831.htm
- SEC Form 10-Q (accession 0001549595-25-000095): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg (NX-5948), zelebrudomide (NX-2127) and NX-1607, and we expect to initiate a Phase 2 clinical trial of bexobrutideg in 2025." https://www.sec.gov/Archives/edgar/data/1549595/000154959525000095/nrix-20250531.htm
- SEC Form 10-Q (accession 0001549595-25-000055): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg (NX-5948), NX-2127 and NX-1607, and we expect to initiate a Phase 2 clinical trial of bexobrutideg in 2025." https://www.sec.gov/Archives/edgar/data/1549595/000154959525000055/nrix-20250228.htm
- SEC Form 10-K (accession 0001549595-25-000016): "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates NX-5948, NX-2127 and NX-1607, and we expect to initiate a Phase 2 clinical trial of NX-5948 in 2025." https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zelebrudomide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zelebrudomide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zelebrudomide

```bibtex
@misc{secapidev_pdufa_zelebrudomide_20261116,
  title        = {Zelebrudomide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zelebrudomide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zelebrudomide_20261116","title":"Zelebrudomide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zelebrudomide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
